"""So if Phase 3 is a success, does that mean we can aim for US$7.5 billion? """
Depends on how big a success. Vascepa's success was a stunner.
On the other hand, AMRN stock is extremely undervalued compared to its potential. So a success on the level of Vascepa's could justify much more than $7b.